106 related articles for article (PubMed ID: 18643853)
1. PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation.
Dong HY; Browne P; Liu Z; Gangi M
Histopathology; 2008 Sep; 53(3):278-87. PubMed ID: 18643853
[TBL] [Abstract][Full Text] [Related]
2. Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma.
Khan MR; Ahmad A; Kayani N; Minhas K
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3463-3466. PubMed ID: 30583670
[TBL] [Abstract][Full Text] [Related]
3. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker.
Torlakovic E; Torlakovic G; Nguyen PL; Brunning RD; Delabie J
Am J Surg Pathol; 2002 Oct; 26(10):1343-50. PubMed ID: 12360049
[TBL] [Abstract][Full Text] [Related]
4. [Expression of B cell-specific activator protein in lymphomas].
Li D; Li GD; Liu WP; Li FY; Zhang WY; Liao DY
Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):345-7. PubMed ID: 16185503
[TBL] [Abstract][Full Text] [Related]
5. Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.
Chu PG; Loera S; Huang Q; Weiss LM
Am J Clin Pathol; 2006 Oct; 126(4):534-44. PubMed ID: 16938666
[TBL] [Abstract][Full Text] [Related]
6. CD20 negative primary diffuse large B cell lymphoma of breast: Role of Pax-5.
Shukla S; Awasthi NP; Singh P; Husain N
J Cancer Res Ther; 2015; 11(3):658. PubMed ID: 26458662
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic uses of Pax5 immunohistochemistry.
Feldman AL; Dogan A
Adv Anat Pathol; 2007 Sep; 14(5):323-34. PubMed ID: 17717432
[TBL] [Abstract][Full Text] [Related]
8. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays.
McCune RC; Syrbu SI; Vasef MA
Mod Pathol; 2006 Jul; 19(7):1010-8. PubMed ID: 16648862
[TBL] [Abstract][Full Text] [Related]
9. PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms.
Desouki MM; Post GR; Cherry D; Lazarchick J
Clin Med Res; 2010 Jul; 8(2):84-8. PubMed ID: 20660931
[TBL] [Abstract][Full Text] [Related]
10. IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.
Teng Y; Takahashi Y; Yamada M; Kurosu T; Koyama T; Miura O; Miki T
Eur J Cell Biol; 2007 Oct; 86(10):581-9. PubMed ID: 17651861
[TBL] [Abstract][Full Text] [Related]
11. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
Mhawech-Fauceglia P; Saxena R; Zhang S; Terracciano L; Sauter G; Chadhuri A; Herrmann FR; Penetrante R
J Clin Pathol; 2007 Jun; 60(6):709-14. PubMed ID: 16837628
[TBL] [Abstract][Full Text] [Related]
12. CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.
Bellan C; De Falco G; Lazzi S; Micheli P; Vicidomini S; Schürfeld K; Amato T; Palumbo A; Bagella L; Sabattini E; Bartolommei S; Hummel M; Pileri S; Tosi P; Leoncini L; Giordano A
J Pathol; 2004 Aug; 203(4):946-52. PubMed ID: 15258998
[TBL] [Abstract][Full Text] [Related]
13. The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease.
O'Brien P; Morin P; Ouellette RJ; Robichaud GA
Cancer Res; 2011 Dec; 71(24):7345-50. PubMed ID: 22127921
[TBL] [Abstract][Full Text] [Related]
14. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.
Garcia JF; Roncador G; García JF; Sánz AI; Maestre L; Lucas E; Montes-Moreno S; Fernandez Victoria R; Martinez-Torrecuadrara JL; Marafioti T; Mason DY; Piris MA
Haematologica; 2006 Apr; 91(4):467-74. PubMed ID: 16585013
[TBL] [Abstract][Full Text] [Related]
15. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.
Montes-Moreno S; Gonzalez-Medina AR; Rodriguez-Pinilla SM; Maestre L; Sanchez-Verde L; Roncador G; Mollejo M; García JF; Menarguez J; Montalbán C; Ruiz-Marcellan MC; Conde E; Piris MA
Haematologica; 2010 Aug; 95(8):1342-9. PubMed ID: 20418245
[TBL] [Abstract][Full Text] [Related]
16. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
17. T-bet, a T cell-associated transcription factor, is expressed in Hodgkin's lymphoma.
Dorfman DM; Hwang ES; Shahsafaei A; Glimcher LH
Hum Pathol; 2005 Jan; 36(1):10-5. PubMed ID: 15712176
[TBL] [Abstract][Full Text] [Related]
18. Loss of CD19 expression in B-cell neoplasms.
Masir N; Marafioti T; Jones M; Natkunam Y; Rüdiger T; Hansmann ML; Mason DY
Histopathology; 2006 Feb; 48(3):239-46. PubMed ID: 16430470
[TBL] [Abstract][Full Text] [Related]
19. Low-grade B-Cell lymphomas with plasmacytic differentiation lack PAX5 gene rearrangements.
George TI; Wrede JE; Bangs CD; Cherry AM; Warnke RA; Arber DA
J Mol Diagn; 2005 Aug; 7(3):346-51. PubMed ID: 16049306
[TBL] [Abstract][Full Text] [Related]
20. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Guedez L; Martinez A; Zhao S; Vivero A; Pittaluga S; Stetler-Stevenson M; Raffeld M; Stetler-Stevenson WG
Blood; 2005 Feb; 105(4):1660-8. PubMed ID: 15479729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
